Genmab A/S (GNMSF)
OTCMKTS · Delayed Price · Currency is USD
285.00
+0.83 (0.29%)
Sep 15, 2025, 12:37 PM EDT
Genmab Employees
Genmab had 2,682 employees as of December 31, 2024. The number of employees increased by 478 or 21.69% compared to the previous year.
Employees
2,682
Change (1Y)
478
Growth (1Y)
21.69%
Revenue / Employee
$1,381,918
Profits / Employee
$519,476
Market Cap
17.33B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 2,682 | 478 | 21.69% |
| Dec 31, 2023 | 2,204 | 544 | 32.77% |
| Dec 31, 2022 | 1,660 | 448 | 36.96% |
| Dec 31, 2021 | 1,212 | 431 | 55.19% |
| Dec 31, 2020 | 781 | 233 | 42.52% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Elite Pharmaceuticals | 68 |
| Tian'an Technology Group | 8 |
| Glass House Brands | 374 |
| Northwest Biotherapeutics | 25 |
| CytoDyn | 13 |
| American Oncology Network | 1,914 |
| Silence Therapeutics | 116 |
Genmab News
- 4 days ago - Genmab: Epkinly's Spectacular Data Is The Antidote To The Darzalex Patent Cliff - Seeking Alpha
- 5 days ago - Genmab: A Matter Of Time - Seeking Alpha
- 7 days ago - Genmab A/S (GMAB) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript - Seeking Alpha
- 7 days ago - Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons - GlobeNewsWire
- 7 days ago - Capital Increase in Genmab as a Result of Employee Warrant Exercise - GlobeNewsWire
- 7 days ago - 10 stocks to consider if you want alternatives to the expensive S&P 500 - Market Watch
- 13 days ago - AbbVie updates mid-stage trial data for Genmab-partnered lymphoma drug in outpatient setting - Seeking Alpha
- 14 days ago - Genmab Announces Updated Results from Phase 2 EPCORE® NHL-6 Study Evaluating Epcoritamab Monotherapy in the Outpatient Setting in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) - Business Wire